Genetix Biotherapeutics Inc. today announced that an analysis of recent patient experience data from the commercial implementation of LYFGENIAtm and ZYNTEGLOtm in the U.S. has been selected for oral ...
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma ...
Entering a cooking adventure as a novice can be intimidating sometimes. So many approaches, unfamiliar foods, and stress from ...